ert.com

– ERT, the global leader in clinical endpoint data collection, today announced that Blue Earth Diagnostics has deployed its innovative imaging solution to support the evaluation of 18F-fluciclovine – a novel PET agent – for potential use in the detection of recurrent brain metastases. As Blue Earth Diagnostics now investigates the compound for evaluating recurrent brain metastases, ERT’s advanced imaging solution is providing a multi-modality platform to centralize the standard of reference process, and is pivotal to the robust assessment of diagnostic performance. After conducting a thorough search of leading imaging providers in the clinical development industry, we chose to work with ERT due to their breadth of experience and flexibility in designing an imaging protocol that fits our study’s complex needs,” said Eugene Teoh, MD, DPhil, Vice President, Clinical Development, Blue Earth Diagnostics and board-certified radiologist. ” Blue Earth Diagnostics is relying on ERT’s advanced imaging solution to determine if 18F-fluciclovine can provide a more effective assessment of recurrent brain metastases than traditional MRI scanning.

Results demonstrate adoption of virtual and wearable technologies to increase effectiveness of CNS studies PHILADELPHIA – February 25, 2021 – ERT, the global leader in clinical endpoint data collection, today released a new report, Innovation Frontiers in CNS Research, which analyzes the results of a recent industry survey on central nervous system (CNS) clinical trials. Fielded in the fourth quarter of 2020, the survey seeks to better understand how a cross-section of key industry professionals from leading pharmaceutical companies are adopting and using new innovations within CNS trials to address challenges specific to this therapeutic area. Current adoption of virtual trial technologies in CNS trials: More than one third of respondents report running fully virtual, or decentralized, CNS trials or a hybrid model featuring some virtual solutions. Manufacturers are looking to innovative patient centric technologies that also offer patients improved convenience like telehealth and at-home data collection to accelerate and improve trial execution” said Jim Mahon, Executive Vice President, Chief Product, Strategy and Marketing Officer, ERT.

Join pharmaceutical and biotech experts to discuss the latest trends and opportunities in the industry at SCOPE Summit, March 2-4 2021. This presentation will focus on problems and solutions created by virtual trials and how technology can support successful patient submission of high-quality data. Matt Johnson, VP of Wearables and Digital Biomarkers at ERT will be a leader in a virtual panel discussion, Make sure to stop by our virtual booth and speak with ERT experts who will be available to answer any of your questions about how to implement virtual solutions in your next clinical trial.

SINCE 2014 Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials Using Cognitive Assessment to Improve Decision Making in Oncology Clinical Trials In the oncology field, there is growing interest in using patient-centered clinical outcome assessments (COAs) in clinical research to determine the potential benefits and safety of new and existing treatments as well as their effects on level of overall function. The assessment of cognition and function in people with cancer entering clinical trials – the application of subjective (PRO) and objective (PerfO) measures Statistical and methodological issues associated with identification of treatment related cognitive dysfunction Dr. Dumais Kelly develops custom site rater training for improving inter-rater reliability, and develops custom patient training for improving accuracy in PRO reporting and patient engagement.